secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001380106-22-000044
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems Q3 commercial revenue $4.7M, net loss $16.3M, reaffirms FY2022 guidance
--------------------------------------------------------------------------------

- Commercial revenue $4.7M (down 25% YoY from $6.3M); recurring revenue up 34% to $2.9M.
- Placed 3 Growth Direct systems in Q3 vs 10 in prior year; validated 4 customer systems.
- Net loss $16.3M ($0.38/share) vs $25.0M ($0.71) in Q3 2021; ops expenses rose on strategic review and restructuring.
- Reaffirms FY2022 revenue at least $17M; expects at least 2 system placements in Q4.
- Cash $150.1M, no debt; strategic review ongoing; restructuring plan targets $8-9M annual savings by Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010622000044/0001380106-22-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010622000044/rpid-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001380106-22-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer